NASDAQ:ATNX Athenex (ATNX) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free ATNX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.20▼$1.5252-Week Range N/AVolume1.88 million shsAverage Volume194,316 shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Athenex alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. About Athenex Stock (NASDAQ:ATNX)Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now. ATNX Stock News HeadlinesDecember 26, 2023 | bizjournals.comBiopharmaceutical company expands in time to take on Athenex businessNovember 22, 2023 | bizjournals.comOnly 2 local CEOs score highly with both employees and investorsApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.July 31, 2023 | bizjournals.comAthenex assets sold in bankruptcy auction; top executives dismissedJune 11, 2023 | fool.comAthenex (NASDAQ: ATNX)June 1, 2023 | bizjournals.comBuffalo's drug development scene expected to continue in Athenex's wakeMay 17, 2023 | bizjournals.comAthenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-AugustMay 16, 2023 | uk.finance.yahoo.comAthenex, Inc. (ATNX) stock price, news, quote & history – Yahoo FinanceApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.May 16, 2023 | msn.comBuffalo Billion project Athenex files for Chapter 11 bankruptcyMay 15, 2023 | msn.comAthenex files Chapter 11May 15, 2023 | bizjournals.comAthenex files for bankruptcy, announces plans to sell assetsMay 15, 2023 | msn.comWhy Athenex (ATNX) Stock Is Getting Obliterated MondayMay 15, 2023 | finance.yahoo.comAthenex Voluntarily Filed For Chapter 11 Proceedings, Shares PlungeMay 15, 2023 | marketwatch.comAthenex Shares Tumble Premarket After Chapter 11 Filing >ATNXMay 15, 2023 | msn.comWhy Is Athenex (ATNX) Stock Down 54% Today?May 15, 2023 | markets.businessinsider.comAthenex Files For Chapter 11 BankruptcyMay 14, 2023 | news.yahoo.comDrugmaker Athenex voluntarily files for U.S. Chapter 11 proceedingsMay 14, 2023 | finance.yahoo.comAthenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ProcessMay 10, 2023 | bizjournals.comPine Pharmaceuticals assumes part of Athenex’s business and 50 workersMay 1, 2023 | finance.yahoo.comQuantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCOApril 24, 2023 | finance.yahoo.comAthenex, Inc. (ATNX) Stock Historical Prices & Data - Yahoo FinanceApril 18, 2023 | bizjournals.comCalifornia-based Biomed Industries offers to buy AthenexMarch 23, 2023 | finance.yahoo.comAthenex (ATNX) Upgraded to Buy: Here's WhyFebruary 14, 2023 | finance.yahoo.comAthenex Announces a Reverse Stock SplitJanuary 3, 2023 | finance.yahoo.comAthenex Announces MHRA Decision on Oral PaclitaxelDecember 31, 2022 | msn.comAthenex to close Clarence plant, lay off 92 employeesSee More Headlines Receive ATNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATNX CUSIPN/A CIK1300699 Webwww.athenex.com Phone(716) 427-2950FaxN/AEmployees652Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-103,430,000.00 Net Margins-86.31% Pretax Margin-95.92% Return on Equity-727.79% Return on Assets-44.44% Debt Debt-to-Equity Ratio3.08 Current Ratio1.09 Quick Ratio0.72 Sales & Book Value Annual Sales$102.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($3.07) per share Price / BookN/AMiscellaneous Outstanding Shares8,660,000Free Float7,866,000Market Cap$1.76 million OptionableOptionable Beta1.36 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesYiu Nam LauChairman & Chief Executive OfficerJeff YordonCOO & President-Athenex Pharmaceutical DivisionJoe AnnoniChief Financial OfficerDarrel P. CohenChief Medical OfficerWilliam ZuoPresident-China OperationsKey CompetitorsPainReformNASDAQ:PRFXGalmed PharmaceuticalsNASDAQ:GLMDBio-PathNASDAQ:BPTHLucy Scientific DiscoveryNASDAQ:LSDIInMed PharmaceuticalsNASDAQ:INMView All Competitors ATNX Stock Analysis - Frequently Asked Questions How were Athenex's earnings last quarter? Athenex, Inc. (NASDAQ:ATNX) issued its earnings results on Thursday, November, 4th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.41) by $0.08. The business earned $32.30 million during the quarter, compared to the consensus estimate of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%. During the same period in the previous year, the company posted ($0.44) earnings per share. What other stocks do shareholders of Athenex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). When did Athenex IPO? Athenex (ATNX) raised $72 million in an initial public offering (IPO) on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager. This page (NASDAQ:ATNX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchThese AI trades triggered this morning (545% return)Prosper Trading AcademyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athenex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
